EYPT vs REGN · rev $1.2M vs P/E 14, rev $4.29B
Eyepoint Pharmaceuticals Inc (EYPT) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Eyepoint Pharmaceuticals Inc (EYPT) is a biotechnology company listed on NASDAQ.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported EYPT revenue for 2026-06-30 was $1.2M. Net income was -$179.3M. Revenue was up 72.8% from 2026-03-31 to 2026-06-30. EYPT currently screens at market cap $1.10B.
Latest reported REGN revenue for 2026-06-30 was $4.29B. Net income was $1.30B. Revenue was up 19.0% from 2026-03-31 to 2026-06-30. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
EYPT currently screens at market cap $1.10B. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the EYPT and REGN stock pages for the full models.
Not investment advice.